These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29519169)

  • 1. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics.
    van den Brink WJ; Hankemeier T; van der Graaf PH; de Lange ECM
    Expert Opin Drug Discov; 2018 Jun; 13(6):539-550. PubMed ID: 29519169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.
    de Lange ECM; van den Brink W; Yamamoto Y; de Witte WEA; Wong YC
    Expert Opin Drug Discov; 2017 Dec; 12(12):1207-1218. PubMed ID: 28933618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats.
    van den Brink WJ; Elassaiss-Schaap J; Gonzalez-Amoros B; Harms AC; van der Graaf PH; Hankemeier T; de Lange ECM
    Eur J Pharm Sci; 2017 Nov; 109():431-440. PubMed ID: 28882765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
    Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Moreno MJ; Ling B; Stanimirovic DB
    Expert Opin Drug Discov; 2020 Aug; 15(8):903-915. PubMed ID: 32396023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of predictive models in CNS diseases.
    Gomeni R
    Curr Opin Pharmacol; 2014 Feb; 14():23-9. PubMed ID: 24565008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.
    Srinivas N; Maffuid K; Kashuba ADM
    Clin Pharmacokinet; 2018 Sep; 57(9):1059-1074. PubMed ID: 29464550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.
    Vuillemenot BR; Korte S; Wright TL; Adams EL; Boyd RB; Butt MT
    Toxicol Sci; 2016 Jul; 152(1):3-9. PubMed ID: 27354708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D
    van den Brink WJ; van den Berg DJ; Bonsel FEM; Hartman R; Wong YC; van der Graaf PH; de Lange ECM
    Br J Pharmacol; 2018 Oct; 175(19):3832-3843. PubMed ID: 30051461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.
    de Lange EC; Ravenstijn PG; Groenendaal D; van Steeg TJ
    AAPS J; 2005 Oct; 7(3):E532-43. PubMed ID: 16353931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Biopharm Drug Dispos; 2014 Nov; 35(8):485-99. PubMed ID: 25044007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
    Caruso A; Alvarez-Sánchez R; Hillebrecht A; Poirier A; Schuler F; Lavé T; Funk C; Belli S
    Biochem Pharmacol; 2013 Jun; 85(11):1684-99. PubMed ID: 23454189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.
    de Lange EC; Hammarlund-Udenaes M
    Clin Pharmacol Ther; 2015 Apr; 97(4):380-94. PubMed ID: 25670219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides.
    Qian S; Wang Q; Zuo Z
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1491-508. PubMed ID: 25196358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New experimental models of the blood-brain barrier for CNS drug discovery.
    Kaisar MA; Sajja RK; Prasad S; Abhyankar VV; Liles T; Cucullo L
    Expert Opin Drug Discov; 2017 Jan; 12(1):89-103. PubMed ID: 27782770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.